We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Ambulatory Surgery Centers Are Becoming ISRG's New Growth Engine
Read MoreHide Full Article
Key Takeaways
Intuitive Surgical placed 27 da Vinci systems at U.S. ASCs in Q2, including 20 refurbished XiR systems.
XiR offers ASCs and smaller hospitals a lower-cost entry point into the fourth-generation da Vinci ecosystem.
Intuitive Surgical plans extended-use EndoWrist instruments in 2027 to lower costs in benign procedures.
Intuitive Surgical (ISRG - Free Report) is focusing on Ambulatory surgery centers (ASCs) as an important channel for its robotic-surgery expansion. The company is targeting the low-cost ASC segment with refurbished XiR platforms priced below its flagship model. This strategy resulted in significant growth in ASC placements during the second quarter.
ISRG placed 27 da Vinci systems at ASCs in the United States, with 20 of those being refurbished XiR platforms. Management also stated that the increase reflected its recent focus on the ASC segment, while describing the placements as part of broader greenfield expansion.
The growing ASC opportunity aligns with the broader shift toward outpatient surgery, where economics and procedure mix can differ substantially from those of traditional hospitals. Intuitive Surgical is addressing this market through a segmented portfolio rather than relying exclusively on its newest and most expensive platforms.
XiR provides a lower-cost entry point while retaining access to the broader fourth-generation da Vinci ecosystem, making robotic surgery more accessible to cost-conscious customers. Management said XiR has been particularly attractive to ASCs and smaller hospitals, while gaining traction internationally.
This strategy could expand Intuitive Surgical’s addressable customer base. Management noted that XiR can introduce robotics to new customers, helping them establish robotic programs and potentially adopt more advanced systems over time. About 130 XiR systems were installed globally over the past year, with approximately 50 in the United States.
Procedure economics could provide another catalyst. Intuitive Surgical plans to introduce extended-use EndoWrist instruments in 2027, targeting lower cost per procedure in high-volume benign procedures. Management specifically linked the initiative to opportunities in benign outpatient procedures and cost-constrained markets.
Thus, ASCs represent more than another sales channel. They provide Intuitive Surgical with an avenue to expand robotic adoption through lower-cost systems, new facilities and potentially broader procedure utilization, while leveraging its established ecosystem.
Peer Updates
Stryker (SYK - Free Report) is positioning its broad orthopedic and MedSurg portfolio to capitalize on the continued migration of procedures toward ASCs. Management said the shift in orthopedic site of care should continue and views ASCs as an opportunity to win across its portfolio, including hips and knees.
The company is also using Mako RPS to address a specific ASC customer segment — surgeons who are not ready to adopt the full Mako platform but want robotic assistance for total-knee procedures. Following a limited second-quarter launch and early conversions, Stryker plans to ramp up Mako RPS commercialization. Its broader ASC strategy also benefits from products across surgical technologies, communications and other portfolio categories.
Zimmer Biomet (ZBH - Free Report) is approaching the ASC market through a combination of technology, surgical products and a broader customer-centric portfolio. Management explicitly identified stronger surgical performance in the second quarter as part of its ASC strategy. Technology remains a major growth driver, supported by a strong robotics pipeline and products spanning large-footprint robotics, handheld technologies, CT and non-CT solutions and mixed reality.
The company is also emphasizing efficiency rather than simply implant pricing in the ASC setting. Management noted that implants account for only about 14-15% of ASC costs, highlighting the importance of reducing surgical time, avoiding inpatient transfers and lowering readmission rates. ZBH is also evaluating adjacent acquisitions in areas where procedures are primarily performed in ASCs.
ISRG’s Price Performance, Valuation and Estimates
Shares of ISRG have lost 30.6% so far this year compared with a 6.9% decline of the industry.
Image Source: Zacks Investment Research
From a valuation standpoint, Intuitive Surgical trades at a forward price-to-earnings ratio of 33.81X, above the industry average. But it is significantly lower than its five-year median of 67.76X. ISRG carries a Value Score of F.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for Intuitive Surgical’s 2026 earnings implies a 20.3% rise from the year-ago period’s level.
View the Zacks #1 Rank List
Image: Shutterstock
Ambulatory Surgery Centers Are Becoming ISRG's New Growth Engine
Key Takeaways
Intuitive Surgical (ISRG - Free Report) is focusing on Ambulatory surgery centers (ASCs) as an important channel for its robotic-surgery expansion. The company is targeting the low-cost ASC segment with refurbished XiR platforms priced below its flagship model. This strategy resulted in significant growth in ASC placements during the second quarter.
ISRG placed 27 da Vinci systems at ASCs in the United States, with 20 of those being refurbished XiR platforms. Management also stated that the increase reflected its recent focus on the ASC segment, while describing the placements as part of broader greenfield expansion.
The growing ASC opportunity aligns with the broader shift toward outpatient surgery, where economics and procedure mix can differ substantially from those of traditional hospitals. Intuitive Surgical is addressing this market through a segmented portfolio rather than relying exclusively on its newest and most expensive platforms.
XiR provides a lower-cost entry point while retaining access to the broader fourth-generation da Vinci ecosystem, making robotic surgery more accessible to cost-conscious customers. Management said XiR has been particularly attractive to ASCs and smaller hospitals, while gaining traction internationally.
This strategy could expand Intuitive Surgical’s addressable customer base. Management noted that XiR can introduce robotics to new customers, helping them establish robotic programs and potentially adopt more advanced systems over time. About 130 XiR systems were installed globally over the past year, with approximately 50 in the United States.
Procedure economics could provide another catalyst. Intuitive Surgical plans to introduce extended-use EndoWrist instruments in 2027, targeting lower cost per procedure in high-volume benign procedures. Management specifically linked the initiative to opportunities in benign outpatient procedures and cost-constrained markets.
Thus, ASCs represent more than another sales channel. They provide Intuitive Surgical with an avenue to expand robotic adoption through lower-cost systems, new facilities and potentially broader procedure utilization, while leveraging its established ecosystem.
Peer Updates
Stryker (SYK - Free Report) is positioning its broad orthopedic and MedSurg portfolio to capitalize on the continued migration of procedures toward ASCs. Management said the shift in orthopedic site of care should continue and views ASCs as an opportunity to win across its portfolio, including hips and knees.
The company is also using Mako RPS to address a specific ASC customer segment — surgeons who are not ready to adopt the full Mako platform but want robotic assistance for total-knee procedures. Following a limited second-quarter launch and early conversions, Stryker plans to ramp up Mako RPS commercialization. Its broader ASC strategy also benefits from products across surgical technologies, communications and other portfolio categories.
Zimmer Biomet (ZBH - Free Report) is approaching the ASC market through a combination of technology, surgical products and a broader customer-centric portfolio. Management explicitly identified stronger surgical performance in the second quarter as part of its ASC strategy. Technology remains a major growth driver, supported by a strong robotics pipeline and products spanning large-footprint robotics, handheld technologies, CT and non-CT solutions and mixed reality.
The company is also emphasizing efficiency rather than simply implant pricing in the ASC setting. Management noted that implants account for only about 14-15% of ASC costs, highlighting the importance of reducing surgical time, avoiding inpatient transfers and lowering readmission rates. ZBH is also evaluating adjacent acquisitions in areas where procedures are primarily performed in ASCs.
ISRG’s Price Performance, Valuation and Estimates
Shares of ISRG have lost 30.6% so far this year compared with a 6.9% decline of the industry.
Image Source: Zacks Investment Research
From a valuation standpoint, Intuitive Surgical trades at a forward price-to-earnings ratio of 33.81X, above the industry average. But it is significantly lower than its five-year median of 67.76X. ISRG carries a Value Score of F.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for Intuitive Surgical’s 2026 earnings implies a 20.3% rise from the year-ago period’s level.
Image Source: Zacks Investment Research
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.